2022
Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2)
Santini V, Platzbecker U, Fenaux P, Giagounidis A, Miyazaki Y, Sekeres M, Xiao Z, Sanz G, Van Hoef M, Ma F, Hertle S, Ramos P, Zeidan A. Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2). Blood 2022, 140: 1340-1342. DOI: 10.1182/blood-2022-160282.Peer-Reviewed Original Research
2020
Racial and Ethnic Disparities Have a Significant Impact on the Outcomes of Patients with Myelodysplastic Syndromes: A Population-Based Study
Goksu S, Khatib J, Goksu B, Wang R, Patel P, Vusirkala M, Cole S, Seyhanli A, Ozer M, Collins R, Chung S, Zeidan A, Madanat Y. Racial and Ethnic Disparities Have a Significant Impact on the Outcomes of Patients with Myelodysplastic Syndromes: A Population-Based Study. Blood 2020, 136: 2-3. DOI: 10.1182/blood-2020-140564.Peer-Reviewed Original ResearchNon-Hispanic blacksCause-specific survivalIncidence rate ratiosNon-Hispanic whitesCox proportional regression modelMedian overall survivalOutcomes of patientsNHB patientsMyelodysplastic syndromeNHW patientsHazard ratioHispanic patientsSurvival outcomesDisease characteristicsIncidence rateRace/ethnicityOverall survivalInsurance statusSurvival analysisAge groupsLonger median overall survivalLarge population-based analysisMultivariable Cox proportional regression modelsHigher incidence rate ratioEarlier population-based studiesPrognostic Models in Myelodysplastic Syndromes
Bewersdorf J, Zeidan A. Prognostic Models in Myelodysplastic Syndromes. 2020, 109-127. DOI: 10.1007/978-3-030-51878-3_7.Peer-Reviewed Original ResearchInternational Prognostic Scoring SystemRisk stratification toolMyelodysplastic syndromeScoring systemStratification toolPrognostic scoring systemClinical trial enrollmentTrial enrollmentPrognostic relevanceDisease characteristicsPatient counselingBody of evidenceTreatment recommendationsPatient subpopulationsIndividual patientsTreatment selectionClinical scenariosPrognostic modelGenetic testingSomatic mutationsSyndromeScoresPatientsPrognostication
2019
Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges
Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Reviews 2019, 36: 70-87. PMID: 31101526, DOI: 10.1016/j.blre.2019.04.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute myeloid leukemiaPatient outcomesMyeloid leukemiaAllogeneic stem cell transplantationEtiology of AMLMinority of patientsStem cell transplantationAge-adjusted incidenceMost older individualsMyeloid progenitor cellsIntensive chemotherapyActive therapyClear etiologyOlder patientsRefractory diseaseSupportive careCurative therapyMedian agePoor prognosisShorter survivalCell transplantationDisease characteristicsEnvironmental DNA-damaging agentsMalignant disordersTherapeutic advances
2016
Disease‐related costs of care and survival among Medicare‐enrolled patients with myelodysplastic syndromes
Zeidan AM, Wang R, Davidoff AJ, Ma S, Zhao Y, Gore SD, Gross CP, Ma X. Disease‐related costs of care and survival among Medicare‐enrolled patients with myelodysplastic syndromes. Cancer 2016, 122: 1598-1607. PMID: 26970288, PMCID: PMC5509410, DOI: 10.1002/cncr.29945.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeEligible patientsHazard ratioMedicare beneficiariesMultivariate Cox proportional hazards modelEnd Results-Medicare databasePropensity score-matched groupsCox proportional hazards modelOverall study populationSubgroup of patientsConfidence intervalsCost-saving interventionEnd of studyProportional hazards modelElderly patientsOverall survivalDisease characteristicsMDS cohortPatient outcomesStudy populationInternational ClassificationWarrants additional researchHazards modelPatientsSurvival rate